Histone methyltransferases such as G9a are required to perpetuate the malignant phenotype [105] and G9a inhibitor BIX-01294 (diazepin-quinazolin-amine derivative) may have therapeutic utility in breast cancer cells overexpressing the methyltransferases [106,107]. The gene discussed is EHMT2; the disease is breast carcinoma.